FDA Cites BlephEx, LLC in 2026-06-03 Warning Letter — Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)
Letter issued · posted to fda.gov .
Subject as published: Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)
TL;DR
Here's the summary: The FDA's Center for Devices and Radiological Health issued a warning letter to BlephEx, LLC (CMS #725861, June 3, 2026) citing violations related to three devices: the BlephEx Powered Eyelid Cleaning Sponge, OptiVize Ophthalmic Battery-Powered Electrolysis Unit, and OptiVize Ophthalmic Forceps. The agency determined that BlephEx marketed the BlephEx Powered Eyelid Cleaning Sponge for treating blepharitis, dry eye disease, and pre-cataract/pre-LASIK patients—uses that deviate from the 2017 FDA determination that classified it as a Class I device exempt from 510(k) notification when intended solely for eyelid hygiene maintenance. BlephEx lacks required premarket approval (PMA), investigational device exemption (IDE), or 510(k) clearance for the marketed indications, rendering the devices adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act.
Argus analysis
# FDA Warning Letter Analysis: BlephEx, LLC
**Company and Findings**
BlephEx, LLC, owned and operated by Dr. James M. Rynerson in Brentwood, Tennessee, manufactures three ophthalmic devices: the BlephEx Powered Eyelid Cleaning Sponge, the OptiVize Ophthalmic Battery-Powered Electrolysis Unit, and the OptiVize Ophthalmic Forceps. During a six-week inspection conducted October 30 through November 19, 2025, the FDA's Center for Devices and Radiological Health determined all three products are unapproved medical devices being distributed without required regulatory clearance. The warning letter, issued June 3, 2026, identifies violations of the Federal Food, Drug, and Cosmetic Act based on website marketing materials and company responses submitted between December 2025 and May 2026.
**Regulatory Citations and Meaning**
The BlephEx device violates 21 CFR § 501(f)(1)(B) for lacking premarket approval (PMA) or investigational device exemption (IDE), and § 502(o) for misbranding—specifically, marketing beyond its stated 510(k)-exempt intended use. Originally approved in 2017 as a Class I eyelid-cleaning device under product code PYU (surgical instrument motors), the company later marketed it for treating blepharitis, dry eye disease, and pre-surgical patients. Similarly, the OptiVize electrolysis unit violates § 501(f)(1)(B) and § 502(o) by exceeding its Class II exemption limitations under 21 CFR § 886.4250, claiming biofilm destruction rather than limited hair follicle destruction. These violations reflect marketing claims that expand intended use beyond cleared or exempt categories, creating unverified safety risks—particularly for vulnerable populations with inflamed or fragile eyelid tissue.
**Timeline and Industry Watch Points**
BlephEx submitted responses through May 29, 2026, but the warning letter indicates no acceptable corrective action occurred. Compliance officers should monitor for FDA enforcement actions, potential injunctions, or product seizures. Industry peers should note that claiming therapeutic benefits (treating disease) versus maintaining hygiene triggers different regulatory pathways. Marketing materials suggesting disease treatment without corresponding 510(k) submissions or PMA approval remain a high-risk compliance area in ophthalmic devices.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
Medical device Warning Letters typically combine QSR observations (21 CFR Part 820) with adulteration (21 USC 351) or misbranding (21 USC 352). Post-market surveillance and MDR reporting (21 CFR Part 803) are recurring subjects.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER BlephEx, LLC MARCS-CMS 725861 — June 03, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Medical Devices Recipient: Recipient Name James M. Rynerson, M.D. Recipient Title Owner & President BlephEx, LLC 330 Franklin Road Suite 135A, Box 117 Brentwood , TN 37027-5252 United States (b)(6) Issuing Office: Center for Devices and Radiological Health United States June 3, 2026 WARNING LETTER CMS #725861 Dear Dr. Rynerson: During an inspection of your firm located in Brentwood, TN from October 30, 2025, through November 19, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the BlephEx Powered Eyelid Cleaning Sponge, the OptiVize Ophthalmic Battery-Powered Electrolysis Unit, and the OptiVize Ophthalmic Forceps. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Unapproved Device Violations Based on our review of the evidence collected during the inspection, your firm’s responses dated December 12, 2025, January 30, 2026, February 27, 2026, March 31, 2026, April 30, 2026, and May 29, 2026, and your firm’s website, www.blephex.com, we determined that the following products are adulterated and misbranded. Specifically: The BlephEx Powered Eyelid Cleaning Sponge is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The BlephEx Powered Eyelid Cleaning Sponge is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction this device into interstate commerce for commercial distribution, intended for a use different from the intended use of a legally marketed device in the generic type of device described at 21 CFR 878.4820 without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a). On July 7, 2017, your firm submitted a request to FDA for information regarding your “Eyelid Cleaning Product” under section 513(g) of the Act. In that request, your firm proposed, in part, that the Eyelid Cleaning Product be regulated under 21 CFR 878.4820 as a class I device exempt from 510(k) notification, specifying an indication for a “battery-operated [eyelid cleaning] device intended to provide power to operate a spinning micro-sponge that cleans the eyelids”. Your firm described the Eyelid Cleaning Product …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a Medical device warning letter?
- Medical device Warning Letters typically combine QSR observations (21 CFR Part 820) with adulteration (21 USC 351) or misbranding (21 USC 352). Post-market surveillance and MDR reporting (21 CFR Part 803) are recurring subjects.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has BlephEx, LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for BlephEx, LLC as of 2026-07-07. Argus ingests new FDA enforcement records daily.
- What FDA violations was BlephEx, LLC cited for?
- The FDA Warning Letter to BlephEx, LLC (issuing office: Center for Devices and Radiological Health) cites: Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k). Classification: Medical device.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites BlephEx, LLC in 2026-06-03 Warning Letter — Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k). Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-blephex-llc-2026-06-03-medical-device
"FDA Cites BlephEx, LLC in 2026-06-03 Warning Letter — Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-blephex-llc-2026-06-03-medical-device.
Argus HQ Research. "FDA Cites BlephEx, LLC in 2026-06-03 Warning Letter — Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-blephex-llc-2026-06-03-medical-device.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_blephex_llc_2026_06_03_medical_device_2026,
title = {FDA Cites BlephEx, LLC in 2026-06-03 Warning Letter — Medical Device/Adulterated/Misbranded/Lacks PMA and/or 510(k)},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-blephex-llc-2026-06-03-medical-device},
note = {Accessed: July 13, 2026}
}